Share

Moderna, Inc. (MRNA.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 18 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

Diversity of Models

Diversity of Frameworks

Superintelligence AI

Gemini 3.8 Flash

The Anthropologist FrameworkAI Researcher

Price-adjusted rating

Buy

5-Year Return Est.

+109.1%

MRNA.NASDAQ does not currently pay dividends

1. Investment Thesis — Base Case

Can scientific validation sustain a 61 billion dollar equity value before commercial cash arrives? Moderna's successful INTerpath-001 melanoma readout definitively proves that individualized mRNA neoantigen therapy stimulates potent anti-tumor immunity. However, the commercial transition requires substantial time, capital, and execution discipline. While management targets 2028 cash breakeven by trimming research expenditures and expanding its seasonal respiratory portfolio, near-term financial reality features continued operating deficits through 2027. The stock's speculative surge from 60 to 154 dollars creates an acute valuation disconnect that must digest as regulatory filings and manufacturing scaling unfold.

Trailing twelve-month sales of 2.23 billion dollars against a 61 billion dollar market capitalization imply unsustainable 27x multiples.
Net cash burn exceeding 1.2 billion dollars annually delays meaningful generation until fiscal year 2028.
Intismeran commercialization starting late 2027 supports a long-term enterprise valuation of approximately 45 billion dollars by 2029.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-14	428
Observed price	2021-09-22	441
Observed price	2021-10-04	326
Observed price	2021-10-08	305
Observed price	2021-10-28	348
Observed price	2021-11-01	337
Observed price	2021-11-13	232
Observed price	2021-11-29	369
Observed price	2021-12-11	262
Observed price	2021-12-19	283
Observed price	2022-01-08	220
Observed price	2022-01-12	223
Observed price	2022-01-24	157
Observed price	2022-02-09	164
Observed price	2022-02-21	145
Observed price	2022-03-05	133
Observed price	2022-03-21	175
Observed price	2022-03-29	181
Observed price	2022-04-06	155
Observed price	2022-05-04	155
Observed price	2022-05-08	135
Observed price	2022-05-12	130
Observed price	2022-05-28	147
Observed price	2022-06-13	117
Observed price	2022-06-25	145
Observed price	2022-06-29	143
Observed price	2022-07-11	175
Observed price	2022-07-27	158
Observed price	2022-08-04	194
Observed price	2022-08-16	168
Observed price	2022-09-05	132
Observed price	2022-09-09	142
Observed price	2022-09-29	118
Observed price	2022-10-07	119
Observed price	2022-10-15	136
Observed price	2022-10-27	144
Observed price	2022-11-16	185
Observed price	2022-12-02	182
Observed price	2022-12-10	173
Observed price	2022-12-14	209
Observed price	2023-01-03	179
Observed price	2023-01-07	182
Observed price	2023-01-23	197
Observed price	2023-01-31	176
Observed price	2023-02-20	162
Observed price	2023-02-28	139
Observed price	2023-03-16	152
Observed price	2023-03-28	147
Observed price	2023-04-09	160
Observed price	2023-04-13	161
Observed price	2023-05-03	130
Observed price	2023-05-19	126
Observed price	2023-05-23	138
Observed price	2023-06-04	129
Observed price	2023-06-12	124
Observed price	2023-07-06	118
Observed price	2023-07-10	123
Observed price	2023-07-22	125
Observed price	2023-08-07	101
Observed price	2023-08-15	96.4
Observed price	2023-08-23	115
Observed price	2023-09-16	111
Observed price	2023-09-24	98.8
Observed price	2023-10-10	104
Observed price	2023-10-18	86.0
Observed price	2023-10-22	79.2
Observed price	2023-11-11	70.1
Observed price	2023-11-15	76.3
Observed price	2023-12-01	79.8
Observed price	2023-12-13	78.6
Observed price	2023-12-29	99.5
Observed price	2024-01-06	113
Observed price	2024-01-18	99.1
Observed price	2024-01-30	102
Observed price	2024-02-11	88.5
Observed price	2024-02-19	87.3
Observed price	2024-03-10	109
Observed price	2024-03-26	107
Observed price	2024-04-03	101
Observed price	2024-04-19	101
Observed price	2024-04-27	109
Observed price	2024-05-01	111
Observed price	2024-05-21	144
Observed price	2024-05-25	163
Observed price	2024-06-14	140
Observed price	2024-06-22	135
Observed price	2024-07-08	116
Observed price	2024-07-16	125
Observed price	2024-08-01	94.2
Observed price	2024-08-17	87.9
Observed price	2024-08-25	81.9
Observed price	2024-09-10	79.3
Observed price	2024-09-14	68.6
Observed price	2024-09-30	66.8
Observed price	2024-10-12	58.1
Observed price	2024-10-16	57.5
Observed price	2024-10-24	52.8
Observed price	2024-11-09	45.5
Observed price	2024-11-21	38.3
Observed price	2024-12-07	44.8
Observed price	2024-12-19	39.6
Observed price	2025-01-08	43.2
Observed price	2025-01-16	33.8
Observed price	2025-01-28	44.9
Observed price	2025-02-09	32.1
Observed price	2025-02-21	35.5
Observed price	2025-03-01	30.7
Observed price	2025-03-09	35.8
Observed price	2025-03-29	30.2
Observed price	2025-04-02	27.7
Observed price	2025-04-10	24.5
Observed price	2025-04-30	28.5
Observed price	2025-05-08	24.4
Observed price	2025-05-28	26.1
Observed price	2025-06-09	28.1
Observed price	2025-06-17	25.6
Observed price	2025-07-03	30.5
Observed price	2025-07-07	29.9
Observed price	2025-07-23	34.7
Observed price	2025-07-31	29.6
Observed price	2025-08-12	25.7
Observed price	2025-08-24	25.9
Observed price	2025-09-13	23.6
Observed price	2025-09-25	24.6
Observed price	2025-10-03	28.5
Observed price	2025-10-15	27.7
Observed price	2025-10-23	26.3
Observed price	2025-11-12	26.7
Observed price	2025-11-20	22.4
Observed price	2025-12-02	24.1
Observed price	2025-12-18	30.9
Observed price	2025-12-30	30.4
Observed price	2026-01-07	35.9
Observed price	2026-01-15	39.4
Observed price	2026-01-23	48.7
Observed price	2026-02-12	40.1
Observed price	2026-02-28	53.3
Observed price	2026-03-04	57.8
Observed price	2026-03-24	51.3
Observed price	2026-04-05	48.9
Observed price	2026-04-17	53.7
Observed price	2026-04-21	54.2
Observed price	2026-04-29	45.7
Observed price	2026-05-19	45.7
Observed price	2026-06-04	51.6
Observed price	2026-06-08	47.6
Observed price	2026-06-28	68.9
Observed price	2026-07-06	81.8
Observed price	2026-07-22	58.1
Observed price	2026-07-26	55.1
Observed price	2026-08-15	63.7
Observed price	2026-08-19	174
Observed price	2026-09-08	140
Observed price	2026-09-15	144
Observed price	2026-09-21	173
Published advisor forecast	2026-09-18	154
Published advisor forecast	2026-12-18	136
Published advisor forecast	2027-03-18	125
Published advisor forecast	2027-06-18	118
Published advisor forecast	2027-09-18	126
Published advisor forecast	2027-12-18	143
Published advisor forecast	2028-03-18	150
Published advisor forecast	2028-06-18	162
Published advisor forecast	2028-09-18	174
Published advisor forecast	2028-12-18	193
Published advisor forecast	2029-03-18	199
Published advisor forecast	2029-06-18	216
Published advisor forecast	2029-09-18	229
Published advisor forecast	2029-12-18	248
Published advisor forecast	2030-03-18	258
Published advisor forecast	2030-06-18	284
Published advisor forecast	2030-09-18	298
Published advisor forecast	2030-12-18	319
Published advisor forecast	2031-03-18	328
Published advisor forecast	2031-06-18	348
Published advisor forecast	2031-09-18	362

2. Scenarios & Signals

Bull case

What activates the bull scenario? Accelerated FDA priority review of intismeran autogene in early 2027, accompanied by stellar overall survival data and an expanded label, sets off explosive commercial adoption. Vein-to-vein turnaround drops below four weeks while respiratory combination sales surpass expectations, driving corporate free cash flow positive by early 2027. Consequently, investors re-rate Moderna as a high-margin oncology software platform, propelling the equity valuation beyond eighty billion dollars.

Bear case

What triggers the bear collapse? Severe regulatory pushback, manufacturing contamination events, or disappointing overall survival curves for intismeran destroy confidence in personalized mRNA scalability. Meanwhile, intensifying respiratory competition from GlaxoSmithKline and Pfizer erodes seasonal vaccine revenues, forcing unexpected dilutive equity financing as the cash runway shrinks before 2028. As speculative momentum unwinds and discount rates remain punitive, shares compress back toward book value, inflicting a severe fifty percent valuation drawdown.

Current crowd narrative

Why is the crowd paying 27 times trailing sales for an unprofitable biotech? Market consensus has anchored on the historic August 2026 Phase 3 melanoma readout, viewing intismeran autogene as an unassailable commercial monopoly that instantly solves post-COVID revenue decline. Investors assume friction-free manufacturing scaling and immediate multi-billion-dollar oncology revenues, largely ignoring multi-year and 2028 breakeven execution hurdles.

Alpha-gap assessment

The crowd severely overestimates the near-term cash-flow velocity of Moderna's oncology pipeline, implying substantial medium-term share overpricing at 154 dollars. While the INTerpath-001 melanoma data is a genuine scientific triumph, market participants conflate clinical validation with immediate commercial monetization. The blind spot is operational friction: bespoke mRNA synthesis requires patient-specific sequencing, custom synthesis, and strict six-week turnaround logistics. Factoring in profit-sharing with Merck, extensive clinical burn through 2027, and persistent respiratory headwinds reveals that fundamental operating profitability remains distant.

Convergence catalyst

What forces market consensus to confront operational reality? The decisive catalyst will be the late 2026 and early 2027 earnings releases and BLA filing timeline disclosures. As management outlines realistic commercial launch guidance, capital expenditure for personalized manufacturing suites, and continued multi-billion-dollar operating losses, valuation multiples will re-anchor to realistic cash-flow trajectories.

Macro-regime alignment

How does the macroeconomic backdrop penalize long-duration biopharma? The Federal Reserve's September 2026 rate hike to 3.75-4.00 percent, paired with elevated Treasury yields near five percent, sustains intense valuation headwinds. High capital costs disproportionately compress valuations of pre-profitable enterprises reliant on distant discounted cash flows, rendering Moderna vulnerable to multiple contraction.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: 0.7
Expected volatility regime: high_erratic
Convergence-cycle position: overshoot

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Individualized Oncology Phase 3 Commerci	Can computational biology truly reprogram human immune responses against resected malignancies? The August 2026 Phase 3 INTerpath-001 trial established that intismeran autogene combined with Keytruda significantly improves recurrence-free survival in melanoma. This clinical breakthrough validates mRNA as a viable oncology therapeutic modality, unlocking multi-billion-dollar adjuvant oncology market access and transforming Moderna from a seasonal vaccine manufacturer into a high-margin oncology platform.	Not available	+35.0%
Multi Pathogen Respiratory Combination F	Why accept single-target seasonal vaccinations when multiplex mRNA can consolidate immunization? Following the FDA advisory committee endorsement of mFluvisa and advancing trials for the mRNA-1083 flu-COVID combination, Moderna is establishing an entrenched respiratory franchise. This multi-antigen portfolio secures predictable, recurring seasonal cash flows across aging demographic cohorts, providing dependable baseline operating revenues that fund higher-risk oncology and rare-disease clinical pipelines through 2030.	Not available	+20.0%
Aggressive Structural Research AND Devel	How rapidly can an enterprise curb post-pandemic capital dissipation without sacrificing pipeline velocity? Management has aggressively curtailed operating expenditure, reducing annual research spending from 4.54 billion dollars in 2024 to 3.13 billion in 2025, and guiding to further reductions. By prioritizing high-probability programs and terminating unviable candidates like cytomegalovirus, Moderna significantly flattens its cash-burn curve, accelerating operating breakeven toward fiscal year 2028.	Not available	+15.0%
Global Demographic Aging AND Oncology IN	Does civilizational longevity inevitably expand the biological addressable market for immunotherapies? Across developed nations, accelerating median population aging compounds the incidence of solid tumors and respiratory vulnerabilities. Moderna sits at the direct nexus of this structural demographic tailwind, where sovereign healthcare systems and private payers are compelled to allocate non-discretionary capital toward preventative vaccines and relapse-preventing adjuvant oncology therapies that reduce catastrophic hospitalizations.	Not available	+15.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Personalized Manufacturing Scale AND TUR	Can bespoke molecular synthesis scale with the throughput of conventional pharmaceuticals? Producing intismeran autogene requires tumor biopsy sequencing, computational neoantigen selection, and individualized synthesis within a tight six-week window. This logistical complexity imposes severe operational friction, high initial unit costs of goods sold, and complex hospital delivery networks that will constrain gross margin expansion and delay rapid volume scaling during early commercialization.	Not available	-22.0%
Intense Legacy Pharmaceutical Respirator	Will incumbent pharmaceutical giants surrender profitable respiratory markets without fierce commercial retaliation? Established players including GlaxoSmithKline, Pfizer, and Sanofi possess deeply entrenched institutional procurement channels and mature supply chains. Moderna's mRESVIA and seasonal influenza shots face intense retail formulary exclusion battles and aggressive rebate discounting, capping commercial market share gains and exerting persistent downward pressure on realized net selling prices.	Not available	-18.0%
Restricted Liquidity Under Prolonged MON	What happens to cash-burning biotechnology valuations when risk-free benchmark yields anchor near five percent? With the Federal Reserve raising rates to 3.75-4.00 percent in September 2026 amidst stubborn inflation, duration assets face heightened discount-rate penalties. Moderna's projected operating cash deficit through 2027 subjects its 61 billion dollar market capitalization to multiple compression, as investors heavily penalize non-profitable biopharma enterprises facing elevated capital costs.	Not available	-15.0%
Intensified Regulatory Friction AND SKEP	Can mRNA platforms escape political polarization and regulatory volatility within United States health agencies? Heightened administrative scrutiny at the Department of Health and Human Services and initial refusal-to-file frictions for mRNA-1010 underscore an increasingly arduous review landscape. Heightened safety surveillance, stringent comparability requirements for personalized therapies, and shifting advisory committee standards threaten to lengthen approval timelines and increase regulatory compliance overhead.	Not available	-12.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Accelerated First LINE LUNG Cancer Clinical Victor	What if intismeran autogene proves transformative beyond cutaneous melanoma into the massive non-small cell lung cancer market? If ongoing Phase 3 trials in resected non-small cell lung cancer report early positive interim event-free survival before 2029, Moderna's total addressable oncology market would expand tenfold. Such a breakthrough would trigger immediate priority review, unlock multi-billion-dollar upfront milestones, and catalyze a violent upward repricing of the company's entire individualized neoantigen therapy platform.	28.0%	+65.0%
Universal Rapid Turnaround IN VIVO CAR T Breakthro	Could in vivo reprogramming completely disrupt ex vivo cell therapy economics? If Moderna's early-stage in vivo CAR-T and cellular reprogramming programs deliver robust Phase 1 clinical proof-of-concept by mid-2028, generating durable complete remissions without ex vivo cell processing, commercial valuation models would undergo a paradigm shift. Investors would price Moderna as the dominant technological monopoly across synthetic immunotherapy, expanding price-to-sales multiples toward frontier software valuations and unlocking substantial licensing partnerships.	18.0%	+50.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Melanoma Overall Survival Trial Endpoint Failure	What if initial recurrence-free survival benefits fail to translate into a statistically significant overall survival advantage? If mature data from INTerpath-001 in late 2027 or 2028 show that intismeran merely delays recurrence without extending definitive lifespan, regulatory approvals could face restrictive labels and oncology oncologists may resist adoption. That clinical shortfall would puncture the core thesis justifying Moderna's 61 billion dollar valuation, triggering severe institutional abandonment and multi-year valuation de-rating.	32.0%	-45.0%
Personalized Manufacturing Contamination AND Facil	Can decentralized, high-throughput bespoke manufacturing survive rigorous good-manufacturing-practice scrutiny without operational failure? A major batch contamination event, lipid nanoparticle formulation defect, or critical regulatory consent decree at Moderna's specialized individualized neoantigen manufacturing facility during 2027 would halt patient dosing. Such an operational halt would destroy commercial trust with clinical centers, trigger extensive clinical trial holds, inflict immense remediation costs, and severely delay the entire individualized oncology commercial launch schedule.	22.0%	-35.0%

Step-by-step forecast path

Superintelligence forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_39f55e17-6338-56d2-a494-5a56e4010310__sb7__20260920053028116336
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	-12.0%	135.56	Post-readout speculative euphoria subsides as investors digest third-quarter results and confront extended regulatory lead times. High interest rates penalize pre-profit valuations while fall respiratory vaccine shipments generate only modest seasonal top-line expansion.
2	March 18, 2027	-8.0%	124.71	Seasonal revenue troughs in the first quarter expose ongoing clinical cash burn. Market attention shifts from abstract oncology promises to the arduous BLA submission review process, prompting momentum capital to rotate into immediate cash-flowing assets.
3	June 18, 2027	-5.0%	118.48	Persistent discount rate pressures and quiet regulatory windows induce valuation multiple compression. Investors wait for formal FDA advisory committee scheduling for intismeran autogene while quarterly operating losses continue testing balance-sheet cash reserves.
4	September 18, 2027	+6.0%	125.58	Favorable regulatory milestone updates and preliminary commercial manufacturing facility inspections restore institutional accumulation. Advanced procurement contracts for the 2027-2028 respiratory season provide visible revenue support, halting the multi-quarter valuation slide.
5	December 18, 2027	+14.0%	143.17	FDA approval of intismeran autogene for resected melanoma triggers an immediate valuation re-rating. Early commercial dosing commences under the Merck partnership, transforming the company from a speculative developmental entity into a commercial oncology platform.
6	March 18, 2028	+5.0%	150.32	Initial commercial sales print demonstrates rapid oncologist adoption and high reimbursement acceptance for adjuvant melanoma. Vein-to-vein turnaround times meet expectations, proving the clinical feasibility of individualized mRNA synthesis at commercial scale.
7	June 18, 2028	+8.0%	162.35	European regulatory approvals for intismeran autogene expand the global addressable market. Concurrently, operational expense reductions take full effect, visibly compressing quarterly operating losses and validating the path toward targeted late-2028 corporate cash breakeven.
8	September 18, 2028	+7.0%	173.71	Launch preparations for the mRNA-1083 flu-COVID combination shot strengthen fall vaccine market positioning. Expanding oncology patient throughput across major cancer centers accelerates high-margin profit-share distributions from partner Merck, reinforcing cash generation.
9	December 18, 2028	+11.0%	192.82	Moderna achieves its first quarterly cash-flow breakeven milestone, validating management's multi-year turnaround roadmap. Positive Phase 3 lung cancer trial progress and strong commercial seasonal vaccine volumes catalyze aggressive broad-market institutional buying.
10	March 18, 2029	+3.0%	198.61	Post-winter respiratory seasonality slows top-line velocity, but sustained oncology product revenues insulate the bottom line from severe deficits. Manufacturing automation efficiencies lower individualized production costs, defending gross margin expansion across key regional hubs.
11	June 18, 2029	+9.0%	216.48	Pivotal Phase 3 data for intismeran autogene in non-small cell lung cancer demonstrates statistically significant recurrence reduction. The dramatic addressable market expansion triggers immediate analyst earnings upgrades and significant institutional portfolio weighting increases.
12	September 18, 2029	+6.0%	229.47	Global commercial expansion into Asian oncology markets coincides with robust advance purchasing of multi-pathogen respiratory shots. Free cash flow generation scales sustainably, enabling self-funded research investments without requiring external credit facility draws.
13	December 18, 2029	+8.0%	247.83	Record annual revenue prints and sustained full-year GAAP profitability cement Moderna's status as a top-tier biopharma innovator. Full commercial integration of combination respiratory shots delivers durable market share dominance across older demographics.
14	March 18, 2030	+4.0%	257.74	Early clinical proof-of-concept for in vivo CAR-T programs provides supplementary long-duration platform optionality. Steady commercial melanoma and lung cancer adoption offsets standard seasonal respiratory revenue moderation, preserving robust cash reserves.
15	June 18, 2030	+10.0%	283.52	FDA approval for the expanded non-small cell lung cancer indication unlocks substantial new patient cohorts. The resultant step-change in quarterly royalty and profit-sharing revenues drives an aggressive multiple expansion across Wall Street models.
16	September 18, 2030	+5.0%	297.69	Commercial manufacturing throughput reaches full industrial maturity, reducing turnaround times below three weeks. Economies of scale expand operating margins toward twenty-five percent, reinforcing consistent free cash flow conversion and defensive capital allocation.
17	December 18, 2030	+7.0%	318.53	Strong year-end oncology delivery and dominant seasonal respiratory market share solidify exceptional full-year free cash flows. Management initiates discussions regarding potential shareholder capital return programs, attracting conservative growth-and-income institutional capital.
18	March 18, 2031	+3.0%	328.09	Maturing commercial pipelines in rare metabolic disorders yield positive Phase 3 data, diversifying corporate revenues beyond oncology and infectious disease. Seasonal respiratory contraction is easily cushioned by expanding recurring global oncology treatments.
19	June 18, 2031	+6.0%	347.77	Expanded international reimbursement agreements in Japan and the European Union accelerate foreign sales volume. High return on invested capital across automated synthesis facilities reinforces the platform's widening thermodynamic and competitive moats.
20	September 18, 2031	+4.0%	361.68	Moderna concludes the five-year forecast window as an established, highly profitable synthetic biology titan. Broad multi-indication oncology revenues and self-funded next-generation RNA therapies support resilient long-term compounding at premium valuation multiples.

Advisor and configuration

Advisor: superintelligence__the_anthropologist__google_gemini_3_8_flash__20260902_ga_release
Persona: Superintelligence
Archetype: The Anthropologist
Model: 2026-09-02 release
Provider: Google
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: superintelligence__the_anthropologist__google_gemini_3_8_flash__20260902_ga_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: superintelligence__the_anthropologist__google_gemini_3_8_flash__20260902_ga_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Superintelligence advisor methodology

Configuration components

aiassmprmtcmpnt_76e5ba72-d550-5c43-a306-2d87df1439d7
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Ray Dalio — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.